TMPRSS2 and COVID-19: For example, numerous studies are evaluating the utility of protease inhibitors of TMPRSS2, alone or in combination with other agents, in COVID-19 patients; these include camostat (11 clinical trials initiated at time of publication, such as NCT04353284, NCT04524663, NCT04470544), nafamostat (NCT04352400, NCT04418128, NCT04390594, NCT04473053), and bromhexine (NCT04424134, NCT04355026, NCT04273763, NCT04340349, NCT04405999).